Canadian man diagnosed with Guillain-Barré Syndrome following 1st dose of ChAdOx1-S vaccine unable to get an exemption from 2nd dose

A ~30-40-year-old male was given a dose of the AstraZeneca vaccine in April 2021. Within days, he started to have excruciating back pain. Then came the tingles on the side of his face — and then, paralysis.

He was diagnosed with Guillain-Barré Syndrome (GBS), a rare condition that affects the nervous system. It can cause paralysis, muscle weakness, and even death. 

This condition has been linked to COVID-19 vaccination with all types of vaccines and wide range of ages (eg, Pfizer: 67-year-old male, Pfizer: 14-year old male,  Astrazeneca: 66-year old male)

Review of 9 cases that occurred in persons with a mean age of 57.8 (range 20–86) years,  56.4% male, showed that most of the reported case-patients received ChAdOx1-S (25/39), followed by BNT162b2 (12/39) (Pfizer-BioNTech), Ad26.COV2.S (1/39) (Johnson & Johnson), and CoronaVac (1/39). The GBS rate after COVID-19 vaccination ranged from 1.8 to 53.2 cases/1 million doses. There were two deaths associated with Ad26.COV2.S-induced GBS in South Africa. 

The Canadian man spent two months in the hospital, and the condition has left him unable to work as he tries to access slow-moving government support for vaccine injury.

He's been unable to get an exemption from receiving the 2nd dose of COVID-19 vaccine, with health officers saying they can't prove his GBS was caused by the AstraZeneca shot — and advising him to get a second dose of a different COVID-19 vaccine. 


REFERENCE

B.C. man who had rare, extreme reaction to COVID-19 vaccine still waiting for exemption, government support | CBC News

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis ...
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an incr...
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high ...
Read more